Unique ID issued by UMIN | UMIN000008005 |
---|---|
Receipt number | R000009415 |
Scientific Title | Japanese Telmisartan versus Irbesartan Therapy to Fasting Hyperglycemic Patients with Hypertension |
Date of disclosure of the study information | 2012/05/21 |
Last modified on | 2012/05/28 15:42:31 |
Japanese Telmisartan versus Irbesartan Therapy to Fasting Hyperglycemic Patients with Hypertension
J-TIGHT
Japanese Telmisartan versus Irbesartan Therapy to Fasting Hyperglycemic Patients with Hypertension
J-TIGHT
Japan |
Fasting hyperglycemic patients with hypertension
Cardiology |
Others
YES
It is known that Peroxisome proliferator-activated receptor-gamma (PPARgamma) could improve insulin resistance. Both telmisartan and irbesartan were angiotensin receptor blockers which have PPARgamma activating action. In this study, we compare the effects of telmisartan and irbesartan to hypertensive patients with fasting hyperglycemia that is one of the causes of the insulin resistance.
Efficacy
Confirmatory
Explanatory
Not applicable
The variation of fasting blood glucose level 24 weeks after medical treatment
1) The variation of blood pressure 24 weeks after medical treatment
2) The variation of fasting insulin, HOMA-IR, HbA1c, adiponectin and high sensitive CRP levels 24 weeks after medical treatment
3) The variation of total cholesterol, low density lipoprotein, high density lipoprotein and triglyceride levels 24 weeks after medical treatment
4) The rate of onset of new diabetes 24 weeks after medical treatment
5) The achievement rate of targeted blood pressure 24 weeks after medical treatment
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Medicine |
telmisartan
40-80 mg/day for 24 weeks
irbesartan
100-200 mg/day for 24 weeks
30 | years-old | <= |
80 | years-old | >= |
Male and Female
1) The patients with more than systolic blood pressure 140 mmHg or diastolic blood pressure 90 mmHg with untreatment or treatment with antihypertensive medications except the inhibitors of renin-angiotensin system (ARB, ACEI, an renin inhibitor, an aldosterone receptor blocker).
2) The fasting blood glucose level is 110 mg/dL and more, and less than 126 mg/dL
1) The patients with secondary hypertension
2) The patients with diagnosed diabetes which are treated with medication
3) The patients received a dialysis treatment
4) The patients with a history of hypersensitivity for test drugs
5) The women who are or may be pregnant
6) The patients with extremely poor bile secretion (total bilirubin more than 2.0 mg/dL) or severe hepatopathy (AST or ALT more than 100I U/L)
7) The patients judged inappropriate by the physicians
100
1st name | |
Middle name | |
Last name | Minoru Yoshiyama |
Osaka City University Medical School
Department of Internal Medicine and Cardiology
1-4-3 Asahi-machi, Abeno-ku, Osaka, Japan
06-6645-3801
1st name | |
Middle name | |
Last name | Yasukatsu Izumi |
Osaka City University Medical School
Department of Pharmacology
1-4-3 Asahi-machi, Abeno-ku, Osaka, Japan
06-6645-3731
Department of Internal Medicine and Cardiology, Osaka City University Medical School
self-sustaining fund
Other
Japan
NO
2012 | Year | 05 | Month | 21 | Day |
Unpublished
Open public recruiting
2011 | Year | 12 | Month | 15 | Day |
2012 | Year | 04 | Month | 01 | Day |
2014 | Year | 09 | Month | 01 | Day |
2012 | Year | 05 | Month | 21 | Day |
2012 | Year | 05 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009415
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |